Ikaria is a critical care company whose innovative therapeutics and interventions address the significant needs of critically ill patients. Our deep understanding of the biology of critical conditions, insight into the clinical picture of critically ill patients, and working knowledge of the needs of critical care providers fuel our efforts. We strive to provide the advanced therapies and clinical support caregivers need to intervene in the most urgent situations.
We are passionate about science
Mark Roth, PhD
At Ikaria, advancing critical care science is crucial. Our scientists are devoted to the study of critical illness. Mark Roth, PhD, founding Ikaria scientist and cell biologist at the Fred Hutchinson Cancer Research Center is a great example of this devotion.